Abstract LB046: Evaluation of<i>TP53</i>mutations in Pap test and blood DNA as novel biomarkers of ovarian cancer risk
Talayeh Ghezelayagh(University of Washington), Rosa Ana Risques(University of Washington), Marc R. Radke(University of Washington), Brendan F. Kohrn(University of Washington), Elizabeth M. Swisher(University of Washington), Jeffrey D. Krimmel‐Morrison(University of Washington), Jeanne Fredrickson(University of Washington), Enna Manhardt(University of Washington)
Cited by 0
Related Papers
Telomere-to-telomere assembly of a complete human X chromosome
|Nature|2020|842
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017
|Journal of the National Comprehensive Cancer Network|2016|660
Genetic/Familial High-Risk Assessment: Breast and Ovarian
|Journal of the National Comprehensive Cancer Network|2010|650
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
|Annals of Oncology|2020|478
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
|Nature Communications|2020|342